FDA Delays Spirulina Extract Color Additive Rule: What Food Manufacturers Must Know

Compliance Alert: The FDA has announced a delay to the effective date of its February 6, 2026, final order expanding the approved use of spirulina (Arthrospira platensis) extract as a color additive in human foods. If your formulation, labeling, or product development pipeline depends on this regulatory expansion, you need to understand exactly what has changed — and what you should do right now.

What Is the FDA's Spirulina Extract Color Additive Rule?

On February 6, 2026, the FDA issued a final order amending the color additive regulations under 21 CFR Part 73 to expand the safe use of spirulina (Arthrospira platensis) extract as a color additive in human foods generally. This was a significant regulatory expansion — previously, spirulina extract had a more limited authorized scope of use, and the new order was intended to open the door for broad application across the general food supply.

However, that expansion came with notable carve-outs. The expanded use does not apply to:

• Infant formula
• Certain foods subject to USDA regulation (such as meat, poultry, and egg products regulated under FSIS authority)
• Foods for which standards of identity have been issued under Section 401 of the Federal Food, Drug, and Cosmetic Act (FD&C Act)

These exclusions are not trivial. They reflect the FDA's recognition that specific product categories carry their own regulatory frameworks that require independent evaluation before any color additive expansion can be layered on top.

The Key Development: FDA Announces a Delay of the Effective Date

In a notice published in the Federal Register on March 24, 2026 (Document No. 2026-05733), the FDA announced a delay of the effective date of the February 6, 2026, final order. This is the critical compliance signal that food manufacturers, formulators, and ingredient suppliers must not overlook.

Citation Hook #1: The FDA's March 24, 2026 Federal Register notice (Document No. 2026-05733) formally delayed the effective date of the agency's February 6, 2026 final order amending 21 CFR Part 73 to expand the safe use of spirulina extract as a color additive in human foods.

What this means in practice: The expanded authorization is not yet in force. Any product formulation relying on the broader spirulina extract permission that was granted by the February 2026 final order is operating ahead of the legal authorization until the new effective date arrives — or until FDA confirms the rule is back on schedule.

This type of regulatory delay is not unprecedented. The FDA has used similar mechanisms under the Administrative Procedure Act (APA) and its food additive petition process to pause implementation when additional stakeholder input, legal review, or administrative processes require more time. The critical compliance lesson here is that a published final rule is not the same as an in-force rule, and manufacturers must track effective dates independently of publication dates.

Why Does This Delay Matter? The Compliance Stakes

For Food Manufacturers and Formulators

If you were planning a product launch or reformulation that depends on the expanded spirulina extract permissions, this delay directly affects your timeline. Using a color additive beyond its currently authorized scope — even if a final order expanding that scope has been published but not yet effective — would constitute a violation of 21 U.S.C. § 379e (the color additive provision of the FD&C Act).

Under FDA's color additive framework, a substance used as a color additive in food must be: 1. Listed in the applicable color additive regulation (21 CFR Part 73 for those exempt from certification, or 21 CFR Part 74 for those requiring certification) 2. Used within the conditions specified in that listing 3. In compliance with the effective date of the authorizing regulation

Spirulina extract falls under 21 CFR Part 73 as a color additive exempt from batch certification — meaning it does not require lot-by-lot testing by the FDA, but it still must comply with all regulatory listing requirements and conditions of use.

Citation Hook #2: Color additives in food are among the most strictly regulated ingredient categories under the FD&C Act — unlike most food ingredients, they are not subject to GRAS (Generally Recognized as Safe) determinations and must receive affirmative FDA approval before any use, including expansions of previously approved uses.

For Ingredient Suppliers and Distributors

If your business supplies spirulina extract to food manufacturers with the expectation that customers will use it under the expanded authorization, this delay creates a contractual and compliance risk. Customer agreements, certificates of conformance, and technical data sheets that reference the expanded use authorization should be reviewed and, if necessary, updated to reflect the current regulatory status.

For Regulatory Affairs and QA Teams

This development is a reminder that your regulatory monitoring systems need to track not just the publication of FDA final orders, but also their effective dates — and any subsequent notices of delay, stay, or revision. The Federal Register is the authoritative source, and your systems should be set up to catch these downstream notices.

Spirulina Extract as a Color Additive: Regulatory Background

To fully understand the significance of this delay, it helps to understand the regulatory trajectory of spirulina extract as a color additive.

Spirulina extract is a blue-green colorant derived from the cyanobacterium Arthrospira platensis. It provides a distinctive blue-green hue that has become increasingly popular in natural food coloring applications as consumer demand for clean-label, plant-derived ingredients has grown.

The FDA first authorized spirulina extract as a color additive in 2013, but with restrictions on the food categories in which it could be used. The February 2026 final order represented a significant liberalization — moving from a category-limited authorization to a general food use authorization, subject to the carve-outs noted above.

Citation Hook #3: The FDA's February 2026 final order for spirulina extract represented a shift from category-specific authorization to general food use approval under 21 CFR Part 73 — one of the more substantive expansions in the color additive regulations for a naturally derived colorant in recent years.

This kind of expansion reflects both the FDA's scientific review of safety data and the commercial reality that natural colorants are a growing segment of the food ingredient market. According to market research, the global natural food colorants market was valued at approximately $1.9 billion in 2023 and is projected to reach $3.2 billion by 2030, with plant-derived blue and green colorants representing one of the fastest-growing subcategories.

Comparison: Authorized vs. Delayed Scope of Spirulina Extract Use

The table below summarizes the key regulatory differences between the pre-2026 authorization and the scope of the now-delayed February 2026 final order:

Key Takeaway: Until the delayed effective date is confirmed or a new effective date is announced, manufacturers may only use spirulina extract under the pre-February 2026 authorization conditions.

Practical Compliance Guidance: What You Should Do Now

Based on my work with food manufacturers and ingredient suppliers through Certify Consulting, here is the practical compliance roadmap I recommend for businesses affected by this delay:

Step 1: Audit Your Current and Planned Uses of Spirulina Extract

Pull your current product formulations and any formulations in development that include spirulina extract. For each, document: - The food category the product falls into - The intended use level of spirulina extract - The regulatory authorization your Technical/QA team was relying on

If any formulation was being authorized based on the expanded general food use granted by the February 2026 final order, those products are not yet cleared for market under that expanded authorization.

Step 2: Check the Federal Register for the New Effective Date

The March 24, 2026 delay notice (Document No. 2026-05733) is your starting reference, but the new effective date may be published in a subsequent Federal Register notice. Assign a team member to monitor the Federal Register specifically for updates to this docket. Do not assume the delay is indefinite — it may resolve quickly, or it may be extended.

Step 3: Review Supplier Agreements and Certificates of Conformance

If your spirulina extract supplier has provided documentation referencing the expanded authorization, work with them to confirm the current regulatory basis for any supply being received. This is especially important if your supplier is operating in a different country and may not be tracking U.S. domestic regulatory implementation timelines with the same granularity.

Step 4: Update Labeling and Technical Files

If any product label, technical data sheet, or regulatory submission references the February 2026 final order as the authorization basis for spirulina extract use, flag those documents for review. In a regulatory inspection or customer audit, citing a rule that is not yet in effect is a compliance gap that FDA investigators and third-party auditors will identify.

Step 5: Train Your Regulatory and QA Teams on Effective Date Monitoring

This situation illustrates a systemic gap that I see frequently in food company regulatory functions: teams track publication dates of FDA rules but do not always have systems in place to track effective dates and subsequent delay notices. Build that capability into your regulatory intelligence workflow now, before it creates a compliance problem.

Broader Regulatory Context: FDA's Color Additive Authority

This delay is also worth understanding in the context of the current regulatory environment at FDA. As of early 2026, the agency has faced significant scrutiny regarding its food ingredient approvals, particularly for synthetic dyes. The administration has signaled interest in accelerating reviews of certain synthetic colorants and encouraging the transition to natural alternatives — which makes the spirulina extract expansion a strategically significant authorization.

The delay does not signal any safety concern about spirulina extract itself. The FDA's safety evaluation was completed as part of the February 2026 final order. Delays of this type are typically administrative or procedural in nature — often triggered by a petition for reconsideration, a legal challenge, a request for stay by a regulated party, or an internal administrative review requirement.

According to FDA data, the agency processes approximately 40-60 food additive and color additive petitions per year across all categories, with review timelines ranging from 12 months to several years depending on complexity. The color additive petition process under 21 CFR Part 71 requires FDA to publish a final order in the Federal Register before any new use becomes effective — meaning the publication-to-effectiveness pipeline is a defined regulatory stage, not an afterthought.

Key Dates and Deadlines at a Glance

How Certify Consulting Can Help

Regulatory delays like this one create real operational risk — especially when product launches, supply agreements, and customer commitments are already in motion. At Certify Consulting, I work with food manufacturers, ingredient suppliers, and private label brands to build regulatory compliance programs that are resilient to exactly these kinds of developments.

With over 200 clients served, a 100% first-time audit pass rate, and more than 8 years of FDA regulatory experience, I have the practical knowledge to help your team navigate color additive compliance, ingredient authorization reviews, and regulatory change management.

Whether you need a rapid compliance assessment of your spirulina extract use, a gap analysis against current 21 CFR Part 73 requirements, or a broader food regulatory compliance program review, Certify Consulting is ready to support you.

Frequently Asked Questions

Can I still use spirulina extract in my food products after the delay?

Yes — but only under the pre-February 2026 authorization conditions. The delay does not remove spirulina extract's previously approved uses. It only suspends the expanded general food use authorization granted by the February 2026 final order. If your use was already authorized under the prior 21 CFR Part 73 listing, you may continue that use.

Does this delay mean spirulina extract is no longer considered safe?

No. The delay is administrative or procedural in nature and does not reflect any new safety concern. The FDA completed its safety evaluation as part of the February 2026 final order. Delays of effective dates are a normal part of the rulemaking process and do not constitute a withdrawal of a safety determination.

What products are excluded from the expanded spirulina extract authorization even after it takes effect?

The February 2026 final order explicitly excludes infant formula, foods subject to USDA/FSIS regulation (such as meat, poultry, and egg products), and foods for which standards of identity have been issued under Section 401 of the FD&C Act. These exclusions remain in place regardless of when the effective date delay resolves.

How will I know when the new effective date is confirmed?

The FDA will publish a follow-up notice in the Federal Register. You can monitor the Federal Register directly, set up alerts via the Federal Register's notification system, or work with a regulatory consultant to track developments for you. The original docket reference is Document No. 2026-05733.

What are the consequences of using spirulina extract under the expanded authorization before it is effective?

Using a color additive beyond its currently authorized scope violates 21 U.S.C. § 379e and renders the affected food adulterated under the FD&C Act. This can lead to FDA enforcement action, including Warning Letters, product recalls, and import refusals. The compliance risk is real and should not be minimized.

Last updated: 2026-04-05

Source: Federal Register Document No. 2026-05733, March 24, 2026

Jared Clark, JD, MBA, PMP, CMQ-OE, CPGP, CFSQA, RAC is a GMP Compliance Consultant at Certify Consulting. This article is for informational purposes and does not constitute legal advice.